Interview with Dimerix's Kathy Harrison
Some interesting points made by Kathy
- Analysts in the USA have identified that drugs such as DMX 200 could potentially command a market of over a billion dollars, based on the high unmet need
- Market capitalisation is only 15 million, comparable companies in the US have market caps 20-50 times that of Dimerix
- Phase II data to be released next month 'exciting', signs are looking good
- Big pharmaceutical companies have been in contact with Dimerix, wants to increase engagement after Phase II results are released in July
- At the end of the year they will commence the Phase II dose expansion 'phase', which will then lead on to Phase III trials
- DMX 200 program has a very achievable path, due to the reduced safety risk
Dimerix's Kathy Harrison discusses pending Phase 2 clinical trials
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
-0.005(1.32%) |
Mkt cap ! $211.7M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 37.0¢ | $156.6K | 414.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 54036 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 7152 | 2 |
View Market Depth
| Last trade - 13.08pm 07/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |